iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib

/in

Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP Competitive Allosteric Modulator Of PI3Kδ, For The Potential Treatment Of Solid And Hematological Tumors Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the […]

Read more

Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre

/in

Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]

Read more

Five companies receive additional financial support through BioInnovation Institute’s Venture House program

/in

BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that five companies are to receive additional financial support through its Venture House program, created to further support former Venture Lab companies through their next phase of growth.   Read more…

Read more

Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology

/in

Founded by Medicxi with Georgia Tech and UMass scientists, supported by US $30M investment from Medicxi Developing advanced, long-lasting therapies for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs Led by dermatology veteran Thibaud Portal as CEO with a Scientific Advisory Board chaired by Nobel Prize Laureate, Craig Mello Boston, Massachusetts, March 16th, […]

Read more

DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

/in

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine. This funding marks the third grant awarded from the Bill […]

Read more